Gerrit Klaerner

USPTO Granted Patents = 49 (Patent Applications = 13)

CIPO Patents = 7 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 5.3

ph-index = 13

Forward Citations = 469(Granted Patents)

Location History:

Campbell, CA (US) (2002 - 2007)
San Jose, CA (US) (1999 - 2013)
San Francisco, CA (US) (2015)
Hillborough, CA (US) (2018)
Los Gatos, CA (US) (2009 - 2021)
Hillsborough, CA (US) (2018 - 2024)

Company Filing History:

Symyx Technologies, Inc.

patents

4. 4 out of 164,108

International Business Machines Corporation

Vifor (international) Ltd.

patents

7. 2 out of 5,303

Leland Stanford Junior University

9. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

49 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11992501 - Compositions for and methods of treating acid-base disorders (2024-05-28),

2. 11986490 - Compositions for and method of treating acid-base disorders (2024-05-21),

3. 11738041 - Proton-binding polymers for oral administration (2023-08-29),

4. 11406661 - HCl-binding compositions for and methods of treating acid-base disorders (2022-08-09),

5. 11311571 - Proton-binding polymers for oral administration (2022-04-26),

6. 11266684 - Compositions for and method of treating acid-base disorders (2022-03-08),

7. 11197887 - Proton-binding polymers for oral administration (2021-12-14),

8. 11123363 - Potassium-binding agents for treating hypertension and hyperkalemia (2021-09-21),

9. 10934380 - Crosslinked poly(allylamine) polymer pharmaceutical compositions (2021-03-02),

10. 10813946 - Potassium binding polymers for treating hypertension and hyperkalemia (2020-10-27),

11. 10485821 - Ion binding polymers and uses thereof (2019-11-26),

12. 10391118 - Proton-binding polymers for oral administration (2019-08-27),

13. 10369169 - Proton-binding polymers for oral administration (2019-08-06),

14. 10363268 - Proton-binding polymers for oral administration (2019-07-30),

15. 10058567 - Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal (2018-08-28),

Title: Gerrit Klaerner: Innovator in Pharmaceutical Compositions

Introduction

Gerrit Klaerner, based in San Jose, CA, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 49 patents. His work primarily focuses on compositions and methods for treating acid-base disorders, which are crucial for improving the physiological conditions of patients.

Latest Patents

Among his latest innovations are two notable patents titled "Compositions for and methods of treating acid-base disorders." These patents describe pharmaceutical compositions that include non-absorbable components aimed at treating various metabolic conditions. One application is particularly geared towards normalizing serum bicarbonate concentrations and blood pH, which is vital for patients suffering from conditions related to acid-base imbalances.

Career Highlights

Gerrit has been instrumental in the success of notable companies such as Relypsa, Inc. and Tricida, Inc., where he applied his knowledge in developing groundbreaking pharmaceutical solutions. His patents and research have played a fundamental role in advancing treatment methodologies in this critical area of medicine.

Collaborations

Throughout his career, Gerrit has collaborated with esteemed professionals such as Dominique Charmot and Jerry M Buysse. These partnerships have fostered an environment of innovation, leading to the development of impactful therapeutic solutions.

Conclusion

Gerrit Klaerner's work exemplifies dedication to advancing medical treatments through innovation. His extensive patent portfolio not only highlights his inventiveness but also serves as a testament to the impact that dedicated professionals can have in the pharmaceutical industry. As research and development in the field continue to evolve, Klaerner's contributions will undoubtedly play a pivotal role in shaping future therapies.

This text is generated by artificial intelligence and may not be accurate.